Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Giordano

Showing results (1-10 of 168) with videos related to

Pageof 17
Sort By:
Current Opinion in Molecular Therapeutics|August 4, 2009
Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancerSilvia Giordano
Hepatology (Baltimore, Md.)|August 3, 2016
miRs*: Innocent bystanders only?Silvia Giordano
Journal of Molecular Medicine (Berlin, Germany)|June 4, 2014
Targeted therapies in cancer and mechanisms of resistanceSimona Corso, Silvia Giordano
Hepatology (Baltimore, Md.)|October 20, 2012
MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?Silvia Giordano, Amedeo Columbano
Trends in Molecular Medicine|June 5, 2016
How Can Gastric Cancer Molecular Profiling Guide Future Therapies?Simona Corso, Silvia Giordano
Frontiers in Oncology|November 25, 2017
Editorial: Metabolism As a Therapeutic TargetAmedeo Columbano, Silvia Giordano
Journal of Hepatology|September 19, 2013
Met as a therapeutic target in HCC: facts and hopesSilvia Giordano, Amedeo Columbano
Cell Cycle (Georgetown, Tex.)|July 21, 2009
MiRNAs as new master playersCristina Migliore, Silvia Giordano
Nature Cell Biology|June 2, 2006
Semaphorin pathways orchestrate osteogenesisLuca Tamagnone, Silvia Giordano
Cancer Discovery|August 1, 2013
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspectiveSimona Corso, Silvia Giordano
Pageof 17

Showing results (1-10 of 168) with videos related to

Sort By:
Pageof 17
Current Opinion in Molecular Therapeutics|August 4, 2009
Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancerSilvia Giordano
Hepatology (Baltimore, Md.)|August 3, 2016
miRs*: Innocent bystanders only?Silvia Giordano
Journal of Molecular Medicine (Berlin, Germany)|June 4, 2014
Targeted therapies in cancer and mechanisms of resistanceSimona Corso, Silvia Giordano
Hepatology (Baltimore, Md.)|October 20, 2012
MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?Silvia Giordano, Amedeo Columbano
Trends in Molecular Medicine|June 5, 2016
How Can Gastric Cancer Molecular Profiling Guide Future Therapies?Simona Corso, Silvia Giordano
Frontiers in Oncology|November 25, 2017
Editorial: Metabolism As a Therapeutic TargetAmedeo Columbano, Silvia Giordano
Journal of Hepatology|September 19, 2013
Met as a therapeutic target in HCC: facts and hopesSilvia Giordano, Amedeo Columbano
Cell Cycle (Georgetown, Tex.)|July 21, 2009
MiRNAs as new master playersCristina Migliore, Silvia Giordano
Nature Cell Biology|June 2, 2006
Semaphorin pathways orchestrate osteogenesisLuca Tamagnone, Silvia Giordano
Cancer Discovery|August 1, 2013
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspectiveSimona Corso, Silvia Giordano
Pageof 17